NCT04340076CompletedPhase 4
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study
Source: ClinicalTrials.gov · Last updated 17 Mar 2026
Brief summary (registry, in English)
The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 244 (actual)
- First submitted
- 20 Mar 2020
- Start date
- 20 Aug 2020
- Primary completion date
- 30 Jan 2025
- Lead sponsor
- Radboud University Medical Center
- Diseases
- Psoriasis
- NCT number
- NCT04340076
- EudraCT number
- 2019-004230-42
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 244
- From 20 Aug 2020 to the primary completion date, 30 Jan 2025
- 19 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc).
Other
- Another indication than plaque psoriasis as the main indication for biologic use (e.g. patient receives biologic for rheumatoid arthritis as the main indication).
- Severe comorbidities with short life-expectancy (e.g. metastasized tumor).
- Presumed inability to follow the study protocol.
Who the study is looking for
- Plaque psoriasis (primarily)
- Treatment for at least 6 months with IL23 or IL17 inhibitor in a normal dose (dose advised by the label)
- PASI≤ 5 at inclusion and in previous 6 months (if no PASI scores are available, it should be clear from the patient record that psoriasis was clear/almost clear in previous 6 months).
- DLQI ≤ 5 at inclusion
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (19)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ULB Erasme Coordinator of this site? Confirm its status | Brussels | Belgium | Unknown status |
| AZ Maria Middelares Coordinator of this site? Confirm its status | Ghent | Belgium | Unknown status |
| AZ St. Lucas Coordinator of this site? Confirm its status | Ghent | Belgium | Unknown status |
| Ghent university hospital Coordinator of this site? Confirm its status | Ghent | Belgium | Unknown status |
| UCL Saint Luc Coordinator of this site? Confirm its status | Leuven | Belgium | Unknown status |
| UZ Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Unknown status |
| CHU Liège Coordinator of this site? Confirm its status | Liège | Belgium | Unknown status |
| Dermatologie Maldegem Coordinator of this site? Confirm its status | Maldegem | Belgium | Unknown status |
| Ziekenhuisgroep Twente Coordinator of this site? Confirm its status | Almelo | Netherlands | Unknown status |
| Bravis hospital Coordinator of this site? Confirm its status | Bergen op Zoom | Netherlands | Unknown status |
| Amphia Hospital Coordinator of this site? Confirm its status | Breda | Netherlands | Unknown status |
| Slingeland Hospital Coordinator of this site? Confirm its status | Doetinchem | Netherlands | Unknown status |
| Catharina hospital Coordinator of this site? Confirm its status | Eindhoven | Netherlands | Unknown status |
| UMC Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Unknown status |
| Maastricht UMC Coordinator of this site? Confirm its status | Maastricht | Netherlands | Unknown status |
| Radboudumc Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Unknown status |
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
| UMC Utrecht Coordinator of this site? Confirm its status | Utrecht | Netherlands | Unknown status |
| Maxima Medisch Centrum Coordinator of this site? Confirm its status | Veldhoven | Netherlands | Unknown status |
Related publications
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.Lancet Reg Health Eur · 2026 · PMID 42577288
This page is information, not medical advice. Discuss any trial with your doctor.